Confronting Aids in Florida With Artificial Intelligence
A University of Florida research team is playing its part to stop the global HIV epidemic, applying the power of artificial intelligence to medical records to uncover patterns of risk and bias that have left some patients in Florida with poor access to today’s effective treatments — so effective that HIV infections are not sexually transmitted.
NCI Grant: Empowering Advanced Imaging Study to Optimize Lung Cancer Outcomes
With a $3.2 million grant from the National Cancer Institute (NCI), investigators from the newly NCI-designated UF Health Cancer Center and the University of Michigan Rogel Cancer Center will work to close evidence gaps in lung cancer care delivery. Over the five-year project, the team will examine the effectiveness of imaging surveillance strategies based on community-identified needs.
UF Health Shands Transplant Center Programs Among Nation’s Best
With patient outcomes in the nation’s top 10%, the UF Health Shands Transplant Center is once again Florida’s foremost destination for transplants. As of July 2023, five organ transplant types demonstrate exceptional results as evaluated by the Scientific Registry of Transplant Recipients, or SRTR.
NovaBone Products Receives 510(k) Clearance for Wound Dressing for the Advanced Wound Market
NovaBone Products, a UF startup and a leader in synthetic biologics, has received clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Wound Matrix product – first of its kind collagen + 45S5 bioactive glass device for the wound care market.
Positive Results in Cancer Vaccine Trial for Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Morphogenesis, Inc., a biotechnology company focused on developing cancer vaccines, in partnership with CohBar, believes they have met their milestone with IFx-HU2.0, a cancer vaccine studied in advanced Merkel cell carcinoma and squamous cell carcinoma.
Kate Therapeutics Debuts With $51 Million Series A To Develop Next-Generation Genetic Medicines To Treat Muscle and Heart Diseases
Kate Therapeutics Inc., a next-generation gene therapy company, has emerged from stealth mode after securing a $51 million Series A financing round. The funding was co-led by Westlake Village BioPartners and Versant Ventures, with participation from Osage University Partners and UF Innovate | Ventures. Additionally, the company has granted Astellas Pharma Inc. an exclusive worldwide license to develop, manufacture, and commercialize KT430 for the treatment of X-linked myotubular myopathy (XLMTM).
EU Adds 9 Startups to Contribute Data to Copernicus Mission
The European Union (EU) has added nine startups — including Spain-based Satlantis, the parent company of UF startup Satlantis LLC — to contribute data to the Copernicus project. Each startup will receive a 5 million euro contract to provide additional data to Copernicus.
UF Startups Among Companies Selected for U.S. Funding to Reduce Carbon Emissions
UF startup Micro Nano Technologies, incubating at UF Innovate | Accelerate at The Hub, is one of six companies sharing $16.2 million in funding for decarbonizing paper and forest products. The goal is to reduce net energy GHG emissions in the paper and forest products industry including increasing the share of renewable energy used, electrification, carbon capture, and energy efficiency.
Aurigo Software Partners With University of Florida To Develop Cutting-Edge Solution for Underwater Projects
Aurigo Software, the leading provider of capital planning and construction management software for infrastructure and private owners, is partnering with the University of Florida’s Department of Mechanical and Aerospace Engineering to develop a revolutionary system for underwater surveying, mapping, and inspection, provisionally named Bathydrone.
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
CohBar, Inc. and Morphogenesis, Inc., a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.